Optimizing the management of her2-positive early breast cancer: the clinical reality

Breast cancer positive for her2 (human epidermal growth factor receptor 2) is associated with a poor prognosis for patients with both early-stage and metastatic breast cancer. Trastuzumab has been shown to be effective and is now considered the standard of care for early-stage patients with her2-pos...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Verma, Su., Lavasani, S., Mackey, J., Pritchard, K., Clemons, M., Dent, S., Latreille, J., Lemieux, J., Provencher, L., Verma, Sh., Chia, S., Wang, B., Rayson, D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Multimed Inc. 2010
Soggetti:
Medical Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2913825/
https://ncbi.nlm.nih.gov/pubmed/20697511
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi